Fighting Hospital-Acquired Infections (HAI) Costs $50B a Year
More than 700,000 antibiotics are prescribed in hospitals every day, but up to 50% of those are for the wrong bacteria. This overuse and misuse of antibiotics has led to a greater incidence of drug-resistant bacteria — or superbugs — in the hospital.
Hospitals bear all of the expenses incurred in HAI — the longer it takes to diagnose and properly treat the pathogen, the costlier it becomes.
Time and Accuracy of Diagnosis Are Critical Factors That Can Cost or Save Lives
80% of hospital-acquired infections are from six species of drug-resistant bacteria.*
In the hospital, traditional blood cultures and drug susceptibility testing can take days to show results.
After blood is drawn from patients, it is incubated for CO2 emission testing (8 hours), then agar plate growth (18 hours), and finally, antibiotic sensitivity testing (24-48 hours).
Traditional Blood Cultures Test for Bacteria – But Too Late
According to the World Health Organization (WHO), “… few infections can be … confirmed in a time span sufficiently short to inform treatment decisions.”†
HEMEMICS offers a significant advantage in post-incubation blood testing, which detects immediately the type of bacteria in blood samples, eliminating the costly and time-consuming steps to identify the proper antibiotic.
48,000 lives are lost each year in the US from bacterial infections.
How HEMEMICS’ Technology Is Changing Healthcare
Results in 60 seconds vs. 48 hours:
How HEMEMICS' Technology Works
Patented Preservative Makes the HEMEMICS “ChipLab” Possible
Our patented HEMSOL™ solution preserves antibodies conjugated with carbon nanotubes on the chip.
This extends shelf life of the antibodies on the chip – NO refrigeration is needed.
HEMEMICS’ proprietary platform – protected by 3 issued patents – liberates diagnostic testing from the central lab. This makes it possible and cost-effective to perform tests at the bedside or in the field for nearly instant answers.
HEMEMICS' technology can rapidly transform the $6B blood culture and $20B immunoassay testing markets.
To find out more about how the HEMEMICS technology can uniquely address COVID-19 and other diagnostic challenges, contact us.